Trimetrexate isethionate
Based on 3 publication(s) in Google Scholar
Trimetrexate (CI-898) isethionate is an antibiotic, also a potent and orally active dihydrofolate reductase (DHFR) inhibitor, reducing the production of DNA and RNA precursors and leading to cell death, with IC50 values of 4.74 nM and 1.35 nM for human DHFR and Toxoplasma gondii DHFR. Trimetrexate isethionate can also inhibit the growth of various cancer cells. Trimetrexate isethionate can be used for researching Pneumocystis carinii pneumonia (PCP) and cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 82935-04-4
- 分子式: C21H29N5O7S
- 分子量:495.55
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Trimetrexate isethionate
MoreAntibiotic アイソフォーム固有の製品をすべて表示
MoreParasite アイソフォーム固有の製品をすべて表示
MoreDNA/RNA Synthesis アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
[1]|
Toxoplasma |
体外実験
Trimetrexate isethionate (0.1 μM; 18 h) completely inhibits proliferation of toxoplasma in murine macrophages[3].
Trimetrexate isethionate (1 μM) can cross the toxoplasma cell membrane and rapidly reaches high intracellular concentrations (108 pmol/107 cells within 10 min) [3].
Trimetrexate (0.1 mM; 24 h) inhibits cell growth by 50-60% in SNU-C4 and NCI-H630 cell lines[5].
Trimetrexate (1 and 10 mM; 24 h) produces lethality and inhibits DHFR in C4 cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SNU-C4 and NCI-H630
-
Concentration:0.1 mM
-
Incubation Time:24 h
-
Result:Inhibited cell growth by 50-60% in both cell lines.
-
Cell Line:C4 cells
-
Concentration:1 and 10 mM
-
Incubation Time:24 h
-
Result:Produced 42% and 50% lethality at 1 and 10 mM, respectively.
体内実験
Trimetrexate (0-30 mg/kg; i.v.; once daily for 5days) isethionate shows chronic toxicity in rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Toxoplasma infected female BALB/c mice weighing about 20 g[3]
-
Dosage:180 mg/kg or 30 mg/kg
-
Administration:180 mg/kg per day orally in the drinking water or 30 mg/kg per day i.p.
-
Result:Extended the median survival of the infected mice to 10 d (p.o.) or 19 d (i.p.).
-
Animal Model:Charles River Wistar Crl(WI)BR rats weighing approximately 150 to 200 g[4]
-
Dosage:0, 1, 10, or 30 mg/kg
-
Administration:Intravenous injection, once daily for 5 consecutive days followed by a 23-day recovery period
-
Result:Showed chronic toxicity, the testicular changes persisting during the course of multiple cycles of dosing were not reversible within 21 days, but required an additional 56 days for essentially complete recovery.
化学情報
-
CAS 番号 82935-04-4
-
分子量 495.55
-
分子式 C21H29N5O7S
-
SMILES
OCCS(=O)(O)=O.NC1=NC(N)=C2C(C)=C(CNC3=CC(OC)=C(OC)C(OC)=C3)C=CC2=N1
-
別名
CI-898 isethionate
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
IQGAP3 bridges matrix stiffness with glioma stem cell maintenance and radioresistance by stabilizing SOX2. [Abstract]2026 Jun 6. PMID: 42251046 -
Sci Data
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]2024 Sep 19;11(1):1024. PMID: 39300112 -
Antimicrob Agents Chemother
Multidrug tolerance conferred by loss-of-function mutations in anti-sigma factor RshA of Mycobacterium abscessus. [Abstract]2024 Dec 5;68(12):e0105124. PMID: 39470195
純度とドキュメンテーション
参考文献
[1]. Hopper AT, et al. Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis. J Med Chem. 2019 Feb 14;62(3):1562-1576. [Content Brief]
[2]. Fulton, B., et al. Trimetrexate. Drugs 49, 563–576 (1995). [Content Brief]
[3]. Allegra CJ, et al. Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate. J Clin Invest. 1987 Feb;79(2):478-82. [Content Brief]
[4]. Dethloff LA, et al. Chronic toxicity of the anticancer agent trimetrexate in rats. Fundam Appl Toxicol. 1992 Jul;19(1):6-14. [Content Brief]
[5]. Grem JL, Voeller DM, Geoffroy F, Horak E, Johnston PG, Allegra CJ. Determinants of trimetrexate lethality in human colon cancer cells. Br J Cancer. 1994 Dec;70(6):1075-84. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Trimetrexate isethionate 関連分類
HY-10373B 関連分類
Powered by Bioz